Protagenic Therapeutics approves 1-for-14 reverse stock split effective May 5, 2025

Protagenic Therapeutics, Inc.new

Reverse stock split at 1-for-14 ratio, effective 12:01 a.m. ET on May 5, 2025.
Intended to bring PTIX into compliance with Nasdaq minimum bid price rule 5550(a)(2).
Share count to drop from ~8.24M to ~588,750; fractional shares rounded up.
Stockholders approved split on April 18, 2025 with ratio range 1:10 to 1:20; board set at 1:14.
Symbol PTIX unchanged; new CUSIP 74365N301; no change in authorized shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.